Pacmilimab
Based on 1 Customer Validation
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.00%
- CAS. Nr.: 2145091-51-4
- Molecular Weight:152.6 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
B7-H1/PD-L1/CD274
In Vivo
Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Product Details
-
CAS. Nr. 2145091-51-4
-
Accession Q9NZQ7
-
Synonyms CX-072
-
Molecular Weight 152.6 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG4 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
95.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)